About Us

Roquefort Therapeutics plc is listed on the London Stock Exchange (LSE:ROQ). We are a team of senior executives with significant experience in establishing and growing businesses in the private and public sectors. Roquefort Therapeutics plc was established to acquire businesses focused on early-stage opportunities in the medical biotechnology sector with the aim of generating optimal returns for both the target businesses and our shareholders.

Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.